These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 991901)

  • 61. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
    Rappa G; Lorico A; Sartorelli AC
    Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice.
    Sieber SM; Whang-Peng J; Botkin C; Knutsen T
    Teratology; 1978 Aug; 18(1):31-47. PubMed ID: 694777
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.
    Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C
    J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents.
    Wozniak AJ; Glisson BS; Hande KR; Ross WE
    Cancer Res; 1984 Feb; 44(2):626-32. PubMed ID: 6318974
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.
    Yalowich JC; Fry DW; Goldman ID
    Cancer Res; 1982 Sep; 42(9):3648-53. PubMed ID: 6179605
    [No Abstract]   [Full Text] [Related]  

  • 66. Effects of the lipophilic anticancer drug teniposide (VM-26) on membrane transport.
    Wright SE; Hines LH; White JC
    Chem Biol Interact; 1990; 75(1):31-48. PubMed ID: 2364457
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Use of VM 26 (epipodophyllotoxin) in treating acute leukemias and lymphomas in the adult].
    Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vygovskaia IaI
    Probl Gematol Pereliv Krovi; 1981 Jul; 26(7):10-4. PubMed ID: 7279889
    [No Abstract]   [Full Text] [Related]  

  • 68. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 69. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 70. VM26-induced changes in hepatic intermediary metabolism of mice.
    Hacker M; Roberts D
    Cancer Res; 1977 Sep; 37(9):3287-92. PubMed ID: 884675
    [No Abstract]   [Full Text] [Related]  

  • 71. Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.
    Slater LM; Stupecky M; Sweet P; Osann KE
    Leuk Res; 2002 Feb; 26(2):203-6. PubMed ID: 11755470
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems.
    Gupta RS; Bromke A; Bryant DW; Gupta R; Singh B; McCalla DR
    Mutagenesis; 1987 May; 2(3):179-86. PubMed ID: 3325741
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 74. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.
    Strife RJ; Jardine I; Colvin M
    J Chromatogr; 1980 May; 182(2):211-20. PubMed ID: 7380913
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of L-1210 leukemia on C11-1431a carbon clearance in DBA-2 mice.
    Ringle DA; Thomson JR
    J Reticuloendothel Soc; 1967 May; 4(2):151-67. PubMed ID: 6057510
    [No Abstract]   [Full Text] [Related]  

  • 76. The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia.
    Rivera GK
    J Clin Oncol; 1988 Feb; 6(2):191-3. PubMed ID: 3276820
    [No Abstract]   [Full Text] [Related]  

  • 77. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
    Bork E; Hansen M; Dombernowsky P; Hansen SW; Pedersen AG; Hansen HH
    J Clin Oncol; 1986 Apr; 4(4):524-7. PubMed ID: 3007684
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Synthesis of spin labeled analogue of podophyllotoxin glycoside].
    Lu K; Chen Y
    Yao Xue Xue Bao; 1998 Dec; 33(12):948-50. PubMed ID: 12016863
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16).
    Long BH
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):3-19. PubMed ID: 1329225
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Automated liquid chromatographic analysis of the anti-tumorigenic drugs etoposide (VP 16-213) and teniposide (VM 26).
    Werkhoven-Goewie CE; Brinkman UA; Frei RW; de Ruiter C; de Vries J
    J Chromatogr; 1983 Sep; 276(2):349-57. PubMed ID: 6630384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.